Generics & Biosimilars | Association for Accessible Medicines
AAM All Access Podcast - Featuring AAM CEO Dan Leonard and leaders in the generics and biosimilars industry.
  • AAM Report: New Generics Are Less Available in Medicare Than Commercial Plans
    New Generics Are Less Available in Medicare Than Commercial Plans
    AAM releases a new report confirming Medicare Part D plans continue to fail to get new generics to patients.
  • AAM All Access Podcast
    AAM All Access Podcast with Dan Leonard
    We're pleased to present the AAM All Access Podcast with our President and CEO Dan Leonard, bringing the story of today’s generics and biosimilars industry to life through the voices of its leaders and health care experts.
  • RxFacts
    What We Know—and What We Don’t
    In the past two decades, misunderstood and exaggerated stats regarding the generics supply chain have been cited.
  • Take with Confidence
    Take With Confidence
    Generic Prescription Drugs: Your Health. Our Commitment.
  • AAM Patient Report: Voices of Access
    Patient Stories: Voices of Access
    AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.